Company / Capital Expenditures
Corbus Pharmaceuticals Holdings, Inc. Capital Expenditures History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$54.2K
FY2022
5-year range
$54.2K / $2.7M
FY2018-FY2022
Trend
-88.8%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $3M to $54,172 over the past 2 years.
Based on SEC 10-K filings.
$54,172 in FY2022 with a 5-year CAGR of -13.8%.
Declined from $3M to $54,172 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -71.3%
- 5-Year CAGR
- -13.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -13.8%, indicating a declining trend.
- In FY2022, capital expenditures decreased 88.8% year-over-year.
- Peak capital expenditures was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -12.48 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $54.2K | -88.8% |
| FY2021 | $484.5K | -82.3% |
| FY2020 | $2.7M | +19.2% |
| FY2019 | $2.3M | +225.2% |
| FY2018 | $707.4K | +520.4% |
| FY2017 | $114.0K | +0.0% |
| FY2016 | $114.0K | +76.9% |
| FY2015 | $64.4K | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026